Psychedelic Stock Review Initiates Coverage on Ehave Inc.
Ryan Allway
September 30th, 2021
Psychedelics
MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Psychedelic Stock Review has initiated coverage.
“Ehave is about to release a number of digital information tools and services made to enhance the effectiveness and practicality of Psychedelic treatments, for both patients and the medical community,” stated Roland Rick Perry, editor of the Biotech and Psychedelic Stock Reviews. Adding, “In 2019 Ehave sold its Clinical Software Platform to Zyus Life Sciences a biopharmaceutical company that offers patients cannabinoid and other phyto-therapeutic medical solutions for $3.2 million.”
Ben Kaplan CEO of Ehave stated, “With the successful sale of the cannabis centric platform that contained components specifically designed to be used by medical cannabis patients to efficiently gather and verify patient-reported outcomes and experiences, evaluate treatment progress, enhance patient engagement and improve data modeling we transitioned the Company to providing these same patient reporting and monitoring services to the Psychedelic industry.”
One of the greatest hurdles faced by Psychedelic patients and clinicians is the lack of a clinical framework to provide effective and reliable dosing and administration regimes. The Ehave Platform can be seamlessly incorporated into clinical trial programs and be a valuable tool for the collection of high-quality data that can be shared with patients and clinicians to validate efficacy in Psychedelic-based treatments, further strengthening its broad adoption world-wide.
“The Ehave patient monitoring and reporting services are essential for Psychedelic treatment clinics and the industry as a whole,” stated Perry. “The opening of Ketamine clinics are moving at a rapid pace. While well tolerated and reported as extremely effective, this is a nascent practice and data needs to collected from thousands of patients currently being treated and the 10’s of thousands who are destined to be treated. With the aid of Ehave’s artificial intelligence, the data provided by a broad set of clinics, can fine tune the practice of administering Ketamine treatments with regards to dosage and treatment times, as well as any potential adverse events. We are excited to initiate coverage on Ehave just as they are about to launch their digital monitoring services.”
Alfred Farrington II, Chief Information Officer of Ehave said, “Ehave is about to launch a suite of products that will give patients better control of their medical records that will improve their overall heath. Powered by AI and predictive medicine our services are designed to enhance the daily lives of patients without boundaries and world-wide. We expect our reporting and monitoring services will greatly contribute to the growth of Ketamine based treatments as well as other Psychedelics as they are approved.”
The Report can be found on the Psychedelic Stock Review website .
Coming Initiatives:
KetaDash 0.1 – Ehave’s KetaDash connects mental health patients with highly skilled nurses to provide ketamine therapy under expert supervision.
MegaTeam [Desktop Version] – Ehave’s MegaTeam assessment and rehabilitation products are built on established methodologies for the measurement of cognitive abilities.
Ninja Reflex [Mobile Version] – Ehave’s Ninja Reflex is a video game intervention for kids with neurodevelopmental disorders.
Ehave Health Records Dashboard (Powered by HealthWizz) – Ehave Dashboard provides Ehave’s users with an easy and user-friendly retrieval and management of medical records, regardless of where the records are hosted. The HIPAA compliant, decentralized mobile platform enables patients to aggregate, organize and share personal medical health records securely and efficiently to anyone, anywhere in the world. The Ehave dashboard finally provides a solution to the serious and widely reported difficulty of patients retrieving their own personal health records.
Ehave Mental Health App by CoggApps – The Ehave Mental Health App by CoggApps is an AI-controlled mental health monitoring tool designed by an MD and PhD-qualified psychiatrist using diagnostic techniques approved by the American Psychiatric Association and the World Health Organization. The platform is based on Apple HealthKit and GoogleFit for data processing and background mental health monitoring.
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Forward-Looking Statement Disclaimer
Institutional Analyst is compensated for providing research coverage for Ehave Inc., please the report for disclosure and disclaimer details.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.
Contact for Ehave
Media Inquiries: Gabe Rodriguez
Email: Gabe@Ehave.com
Investor Relations:
Email: Ir@Ehave.com
Phone: (623) 261-9046
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
KetamineOne Capital is focused on consolidating medical clinics and becoming a North American leader in mental health treatments.
Quadron Cannatech Corporation is a Vancouver based automated extraction and processing solutions company.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
